These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33684256)

  • 41. Nusinersen treatment response markers.
    Fyfe I
    Nat Rev Neurol; 2022 Jul; 18(7):381. PubMed ID: 35676372
    [No Abstract]   [Full Text] [Related]  

  • 42. Nusinersen helps restore walking ability in childhood spinal muscular atrophy.
    Sugimoto M; Aiba K; Koyama N; Yokochi K; Nishio H
    Pediatr Int; 2019 Jul; 61(7):728-729. PubMed ID: 31290219
    [No Abstract]   [Full Text] [Related]  

  • 43. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
    Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
    Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Respiratory outcomes post nusinersen in spinal muscular atrophy type 1.
    Gonski K; Fitzgerald DA
    Pediatr Pulmonol; 2021 May; 56(5):807-808. PubMed ID: 33316146
    [No Abstract]   [Full Text] [Related]  

  • 45. Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy.
    LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
    Am J Respir Crit Care Med; 2019 Dec; 200(12):1547-1550. PubMed ID: 31433957
    [No Abstract]   [Full Text] [Related]  

  • 46. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.
    Wurster CD; Steinacker P; Günther R; Koch JC; Lingor P; Uzelac Z; Witzel S; Wollinsky K; Winter B; Osmanovic A; Schreiber-Katz O; Al Shweiki R; Ludolph AC; Petri S; Hermann A; Otto M;
    J Neurol; 2020 Jan; 267(1):36-44. PubMed ID: 31552549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes in type 1 spinal muscular atrophy on nusinersen: A single center experience.
    Kaltman J; Kern-Smith E; Zhang C; Figueroa J; Ritchey M; Razdan R; Verma S
    Clin Neurophysiol; 2020 Dec; 131(12):2793-2794. PubMed ID: 33130439
    [No Abstract]   [Full Text] [Related]  

  • 48. Nusinersen for Type 1 Spinal Muscular Atrophy: A Father's Perspective.
    Hoot NR
    Pediatrics; 2019 Oct; 144(4):. PubMed ID: 31506303
    [No Abstract]   [Full Text] [Related]  

  • 49. Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis.
    Coratti G; Cutrona C; Pera MC; Bovis F; Ponzano M; Chieppa F; Antonaci L; Sansone V; Finkel R; Pane M; Mercuri E
    Orphanet J Rare Dis; 2021 Oct; 16(1):430. PubMed ID: 34645478
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
    De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG
    J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Surgical correction of a ventricular septal defect in a child with spinal muscular atrophy type 2 treated with nusinersen sodium: a case report.
    Biçer M; Kozan Ş; Öztürk F; Akçay AA
    J Cardiothorac Surg; 2023 Feb; 18(1):68. PubMed ID: 36759863
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.
    Haché M; Swoboda KJ; Sethna N; Farrow-Gillespie A; Khandji A; Xia S; Bishop KM
    J Child Neurol; 2016 Jun; 31(7):899-906. PubMed ID: 26823478
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy.
    Chacko A; Sly PD; Gauld L
    Am J Respir Crit Care Med; 2020 Mar; 201(5):624. PubMed ID: 31747298
    [No Abstract]   [Full Text] [Related]  

  • 54. Anesthetic management of pediatric patients undergoing intrathecal nusinersen administration for treatment of spinal muscular atrophy: A single-center experience.
    Brollier LD; Matuszczak M; Marri T; Carbajal JG; Moorman AT; Sorial EM; Jain R
    Paediatr Anaesth; 2021 Feb; 31(2):160-166. PubMed ID: 32623818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Nusinersen in the treatment of spinal muscular atrophy].
    Sinkó G; Kiss Z; Kalman B
    Ideggyogy Sz; 2018 Mar; 71(3-04):90-94. PubMed ID: 29889467
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.
    Bianchi L; Sframeli M; Vantaggiato L; Vita GL; Ciranni A; Polito F; Oteri R; Gitto E; Di Giuseppe F; Angelucci S; Versaci A; Messina S; Vita G; Bini L; Aguennouz M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sleep and Breathing After Nusinersen Therapy in a Child With Spinal Muscular Atrophy.
    Kouri I; Demirel N; Haile DT; Selcen D; Kotagal S
    J Clin Neuromuscul Dis; 2020 Dec; 22(2):105-108. PubMed ID: 33214397
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
    Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
    Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
    Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
    N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Delivery of Nusinersen Through an Ommaya Reservoir in Spinal Muscular Atrophy.
    Iannaccone ST; Paul D; Castro D; Weprin B; Swift D
    J Clin Neuromuscul Dis; 2021 Mar; 22(3):129-134. PubMed ID: 33595996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.